

# Thomas M Habermann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9608584/publications.pdf>

Version: 2024-02-01

265  
papers

6,778  
citations

126907

33  
h-index

69250

77  
g-index

282  
all docs

282  
docs citations

282  
times ranked

8068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. <i>American Journal of Hematology</i> , 2022, 97, 151-159.	4.1	0
2	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	5.2	9
3	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. <i>Blood Cancer Journal</i> , 2022, 12, 1.	6.2	7
4	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022, 12, 18.	6.2	9
5	Marginal zone lymphoma: present status and future perspectives. <i>Haematologica</i> , 2022, 107, 35-43.	3.5	22
6	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	4.1	2
7	Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 787975.	2.4	11
8	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.4	2
9	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	6.2	1
10	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	2.9	0
11	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	7.2	28
12	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 475-483.	4.7	45
13	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021, 62, 271-280.	1.3	6
14	Testicular <sup>FDG</sup>PET</sup>/<sup>CT</sup> uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	4.1	3
15	Treatment facility volume and patient outcomes in Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	1.3	3
16	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	4.7	67
17	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
18	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 8.	6.2	9

#	ARTICLE	IF	CITATIONS
19	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021, 149, 535-545.	5.1	4
20	Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. <i>Blood Advances</i> , 2021, 5, 1379-1387.	5.2	18
21	Epidemiology of marginal zone lymphoma. <i>Annals of Lymphoma</i> , 2021, 5, 1-1.	4.5	51
22	Relapsed/Refractory International Prognostic Index (R <sup>2</sup> -IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021, 96, 599-605.	4.1	8
23	Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. <i>Kidney International Reports</i> , 2021, 6, 1050-1057.	0.8	1
24	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	1.6	60
25	Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 423-430.	2.4	10
26	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	1.6	16
27	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021, 96, 979-988.	4.1	5
28	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	4.1	12
29	Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	1
30	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	1.3	5
31	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	6.2	4
32	Lack of intrafollicular memory CD4 <sup>+</sup> T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	6.2	27
33	Lines of therapy before autologous stem cell transplant and CAR <sup>T</sup> affect outcomes in aggressive Non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2021, 96, E386-E389.	4.1	4
34	Epstein Barr Virus-Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. <i>Kidney International Reports</i> , 2021, 6, 2223-2227.	0.8	0
35	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021, 39, 658-663.	1.7	8
36	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	2.5	12

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. <i>HemaSphere</i> , 2021, 5, e640.	2.7	7
38	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	6.2	3
39	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. <i>Blood</i> , 2021, 138, 1327-1327.	1.4	0
40	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	1.4	1
41	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	1.4	1
42	Vaccination History and Risk of Lymphoma and Its Major Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, , cebp.0383.2021.	2.5	1
43	Central Nervous System Involvement By Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2426-2426.	1.4	1
44	Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. <i>Blood</i> , 2021, 138, 1348-1348.	1.4	0
45	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	1.4	2
46	Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. <i>Blood</i> , 2021, 138, 815-815.	1.4	0
47	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	1.4	1
48	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	1.4	0
49	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	1.4	1
50	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	1.4	0
51	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1439-1439.	1.4	0
52	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808.	1.4	0
53	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020, 105, 348-357.	3.5	105
54	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. <i>Leukemia and Lymphoma</i> , 2020, 61, 298-308.	1.3	15

#	ARTICLE	IF	CITATIONS
55	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	1.3	9
56	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	5.8	22
57	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	2.5	41
58	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	4.1	33
59	Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B. <i>British Journal of Haematology</i> , 2020, 191, e41-e43.	2.5	2
60	Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2217-2222.	2.0	7
61	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	1.3	2
62	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	6.2	18
63	Analysis and impact of a multidisciplinary lymphoma virtual tumor board. <i>Leukemia and Lymphoma</i> , 2020, 61, 3351-3359.	1.3	14
64	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. <i>Lancet Haematology</i> , 2020, 7, e490-e497.	4.6	14
65	High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?. <i>Blood Cancer Journal</i> , 2020, 10, 5.	6.2	22
66	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. <i>Oncologist</i> , 2020, 25, 689-695.	3.7	7
67	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020, 189, 661-671.	2.5	12
68	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	1.4	2
69	Lines of Therapy before Autologous Stem Cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2020, 136, 29-30.	1.4	3
70	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
71	Long-Term Results of the Treatment of Persons with Hodgkin's Lymphoma in a Resource-Constrained Setting: Real-World Data from a Single Center. <i>Blood</i> , 2020, 136, 33-34.	1.4	0
72	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
74	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
75	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
76	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	1.4	0
77	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
78	Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study. <i>Blood</i> , 2020, 136, 45-46.	1.4	0
79	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
80	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
81	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
82	Waldenström Macroglobulinemia in the Very Elderly (≥75 years): Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	1.4	8
83	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	1.4	26
84	Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2271-2277.	1.3	8
85	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	6.2	37
86	Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2676-2688.	2.8	38
87	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	2.5	12
88	Impact of lymphoma survivorship clinic visit on patient-centered outcomes. <i>Journal of Cancer Survivorship</i> , 2019, 13, 344-352.	2.9	8
89	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	4.1	15
90	Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	4.1	1

#	ARTICLE	IF	CITATIONS
91	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. American Journal of Hematology, 2019, 94, 658-666.	4.1	19
92	<i>Cryptococcus neoformans</i> infections in patients with lymphoproliferative neoplasms. Leukemia and Lymphoma, 2019, 60, 920-926.	1.3	11
93	Acute coronary syndromes in patients with active hematologic malignancies – Incidence, management, and outcomes. International Journal of Cardiology, 2019, 275, 6-12.	1.7	27
94	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia, 2019, 33, 790-794.	7.2	28
95	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990–2018. American Journal of Hematology, 2019, 94, 291-298.	4.1	40
96	Bleomycin Use in the Treatment of Hodgkin Lymphoma (HL): Toxicity and Outcomes in the Modern Era. Blood, 2019, 134, 4038-4038.	1.4	1
97	Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC). Blood, 2019, 134, 400-400.	1.4	2
98	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. Blood, 2019, 134, 1610-1610.	1.4	3
99	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. Blood, 2019, 134, 121-121.	1.4	7
100	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). Blood, 2019, 134, 69-69.	1.4	9
101	Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience. Blood, 2019, 134, 4129-4129.	1.4	1
102	Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values. Blood, 2019, 134, 2811-2811.	1.4	1
103	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. Blood, 2019, 134, 1532-1532.	1.4	0
104	Characteristics of Patients with Relapsed/Refractory Burkitt Non-Hodgkin Lymphoma (NHL): Impact on the Feasibility of CAR-T Cell Therapy. Blood, 2019, 134, 5352-5352.	1.4	0
105	Impact of Acute Kidney Injury Following Diagnosis of Aggressive Lymphoma or Acute Leukemia on Long-Term Kidney Outcomes. Blood, 2019, 134, 1628-1628.	1.4	0
106	Inferior Outcomes for Older Patients in the Adolescent and Young Adult (AYA) Population with Burkitt Lymphoma Treated with Intensive Immunochemotherapy: An International Study of 108 Patients. Blood, 2019, 134, 4113-4113.	1.4	0
107	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. Blood, 2019, 134, 5215-5215.	1.4	0
108	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Blood, 2019, 134, 919-919.	1.4	0



#	ARTICLE	IF	CITATIONS
109	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019, 134, 923-923.	1.4	0
110	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	1.4	0
111	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019, 134, 422-422.	1.4	0
112	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5293-5293.	1.4	2
113	Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL). <i>Blood</i> , 2019, 134, 4010-4010.	1.4	1
114	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
115	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	1.8	71
116	Post-Transplantation Lymphoproliferative Disorders in Adults. <i>New England Journal of Medicine</i> , 2018, 378, 549-562.	27.0	303
117	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	1.3	5
118	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
119	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	4.1	57
120	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	2.5	5
121	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	2.0	4
122	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	4.1	16
123	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	2.5	20
124	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	6.2	26
125	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	4.1	24
126	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	1.7	13



#	ARTICLE	IF	CITATIONS
127	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	3.5	52
128	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 664-672.e2.	0.4	6
129	An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation. <i>Blood</i> , 2018, 132, 2247-2247.	1.4	2
130	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	1.4	1
131	Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD). <i>Blood</i> , 2018, 132, 456-456.	1.4	4
132	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	1.4	1
133	Depth of Response in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 4141-4141.	1.4	2
134	Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 4208-4208.	1.4	0
135	<i>FCGR3A</i> / <i>2A</i> polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
136	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	4.1	26
137	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	2.5	15
138	Rituximab maintenance improves overall survival of patients with follicular lymphoma—Individual patient data meta-analysis. <i>European Journal of Cancer</i> , 2017, 76, 216-225.	2.8	50
139	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma — tissue remains the issue. <i>Leukemia and Lymphoma</i> , 2017, 58, 2342-2348.	1.3	10
140	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	7.1	110
141	Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793); Tj ETQq1 1i0b784314rgBT /Ome		
142	Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. <i>International Journal of Dermatology</i> , 2017, 56, 1125-1129.	1.0	12
143	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	2.5	25
144	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. <i>Oncologist</i> , 2017, 22, 1415-1418.	3.7	7

#	ARTICLE	IF	CITATIONS
145	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
146	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	2.5	49
147	Changes in Quality of Life in Indolent Non-Hodgkin Lymphoma 3 Years after Diagnosis. <i>Blood</i> , 2017, 130, 917-917.	1.4	4
148	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017, 130, 914-914.	1.4	2
149	Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e354-e366.	3.8	4
150	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	4.1	41
151	Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 151-157.	2.5	3
152	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	1.4	1
153	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	1.4	1
154	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". <i>Blood</i> , 2016, 128, 1750-1750.	1.4	2
155	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	1.4	4
156	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	1.4	2
157	Utility of Progression-Free Survival at 24 Months (PFS24) to Predict Subsequent Outcome for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Enrolled on Randomized Clinical Trials: Findings from a Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 5853 Patients. <i>Blood</i> , 2016, 128, 3027-3027.	1.4	5
158	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	1.4	5
159	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	1.4	5
160	Evaluation of Progression-Free Survival (PFS) As a Surrogate Endpoint for Overall Survival (OS) in First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): Findings from the Surrogate Endpoint in Aggressive Lymphoma (SEAL) Analysis of Individual Patient Data from 7507 Patients. <i>Blood</i> , 2016, 128, 4196-4196.	1.4	1
161	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	1.4	8
162	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	1.4	1

#	ARTICLE	IF	CITATIONS
163	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	1.4	0
164	Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis. <i>Blood</i> , 2016, 128, 5480-5480.	1.4	1
165	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	1.4	0
166	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 5322-5322.	1.4	0
167	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 107-107.	1.4	0
168	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. <i>American Journal of Hematology</i> , 2015, 90, 790-795.	4.1	221
169	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	1.4	92
170	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. <i>Nature Medicine</i> , 2015, 21, 922-926.	30.7	927
171	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). <i>Oncologist</i> , 2015, 20, 1149-1153.	3.7	52
172	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015, 56, 2365-2372.	1.3	2
173	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2683-2683.	1.4	6
174	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	1.4	1
175	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). <i>Blood</i> , 2015, 126, 813-813.	1.4	1
176	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	1.4	17
177	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 131-131.	1.4	0
178	Lymphocyte-to-Monocyte Ratio at Diagnosis and Survival in De Novo Double/Triple Hit Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3885-3885.	1.4	0
179	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	1.4	0
180	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014, 2014, 130-144.	2.1	265
182	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
183	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	1.4	5
184	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	1.4	2
185	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013, 122, 4179-4179.	1.4	4
186	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 631-631.	1.4	1
187	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. <i>Blood</i> , 2013, 122, 844-844.	1.4	5
188	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	1.4	1
189	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. <i>Blood</i> , 2013, 122, 4288-4288.	1.4	0
190	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. <i>Blood</i> , 2013, 122, 1774-1774.	1.4	0
191	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , 2013, 122, 626-626.	1.4	0
192	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. <i>Blood</i> , 2013, 122, 841-841.	1.4	0
193	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2013, 122, 4306-4306.	1.4	0
194	The clinical spectrum of Castleman's disease. <i>American Journal of Hematology</i> , 2012, 87, 997-1002.	4.1	184
195	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	1.4	2
196	Primary Breast Diffuse Large B Cell Lymphoma: A Distinct Clinical Entity. <i>Blood</i> , 2012, 120, 1618-1618.	1.4	2
197	Response-Adapted Therapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL)Based On Early [18F] FDG-PET Scanning: An Eastern Cooperative Oncology Group Study (E3404). <i>Blood</i> , 2012, 120, 687-687.	1.4	4
198	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	1.4	8

#	ARTICLE	IF	CITATIONS
199	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. <i>Blood</i> , 2012, 120, 1525-1525.	1.4	0
200	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Interim Positron-Emission Tomography in Predicting Progression-Free Survival and Time to Progression in Classical Hodgkin Lymphoma (HL). <i>Blood</i> , 2012, 120, 1527-1527.	1.4	0
201	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ“) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012, 120, 1604-1604.	1.4	1
202	Long Term Clinical Outcomes in Patients with Massive Splenomegaly and Non-Hodgkin's Lymphoma Treated with Splenectomy.. <i>Blood</i> , 2012, 120, 2692-2692.	1.4	3
203	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	1.4	0
204	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1534-1534.	1.4	0
205	Differences in Outcomes in Males and Females with Diffuse Large B-Cell Lymphoma with Induction Rituximab and Follicular Lymphoma Treated with Maintenance Rituximab. <i>Blood</i> , 2012, 120, 3705-3705.	1.4	0
206	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	1.4	0
207	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	1.4	0
208	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2012, 120, 1573-1573.	1.4	0
209	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. <i>Blood</i> , 2012, 120, 2634-2634.	1.4	0
210	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	1.4	0
211	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	1.4	0
212	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment â€“ a Single Institution Experience. <i>Blood</i> , 2011, 118, 1580-1580.	1.4	1
213	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. <i>Blood</i> , 2011, 118, 1603-1603.	1.4	3
214	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. <i>Blood</i> , 2011, 118, 1640-1640.	1.4	1
215	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011, 118, 2656-2656.	1.4	26
216	Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era. <i>Blood</i> , 2011, 118, 879-879.	1.4	3

#	ARTICLE	IF	CITATIONS
217	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. <i>Blood</i> , 2011, 118, 94-94.	1.4	4
218	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011, 118, 429-429.	1.4	1
219	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011, 118, 3652-3652.	1.4	0
220	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011, 118, 87-87.	1.4	1
221	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. <i>Blood</i> , 2011, 118, 1926-1926.	1.4	0
222	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. <i>Blood</i> , 2011, 118, 1572-1572.	1.4	0
223	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. <i>Blood</i> , 2011, 118, 3642-3642.	1.4	0
224	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. <i>Blood</i> , 2011, 118, 85-85.	1.4	1
225	The Mutational Landscape of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011, 118, 259-259.	1.4	0
226	Potential Pathogenetic Role of <i>Achromobacter</i> ( <i>Alcaligenes</i> ) <i>Xylosoxidans</i> in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG. <i>Blood</i> , 2011, 118, 880-880.	1.4	2
227	ASH 2009 meeting reportâ€”Top 10 clinically oriented abstracts in lymphoma. <i>American Journal of Hematology</i> , 2010, 85, 280-283.	4.1	0
228	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010, 116, 287-287.	1.4	5
229	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes â€” Single Institution Experience. <i>Blood</i> , 2010, 116, 4168-4168.	1.4	5
230	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010, 116, 991-991.	1.4	1
231	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	1.4	10
232	Complementary and alternative medicine use among longâ€”term lymphoma survivors: A pilot study. <i>American Journal of Hematology</i> , 2009, 84, 795-798.	4.1	49
233	Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for WaldenstrÃ¶mâ€™s macroglobulinemia. <i>Clinical and Experimental Nephrology</i> , 2008, 12, 292-295.	1.6	22
234	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 121-121.	1.4	31



#	ARTICLE	IF	CITATIONS
235	Prevalence of Post-Transplant Lymphoproliferative Disorder with Monoclonal Gammopathy of Unknown Significance in Patients Undergoing Kidney Transplantation.. Blood, 2007, 110, 4778-4778.	1.4	0
236	Pre Transplantation MGUS and Transformation to Multiple Myeloma in Kidney Transplantation: A Single Center Experience.. Blood, 2007, 110, 4779-4779.	1.4	0
237	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 124-124.	1.4	2
238	Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 3121-3127.	1.6	1,203
239	Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.. Blood, 2006, 108, 2729-2729.	1.4	5
240	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. Blood, 2006, 108, 530-530.	1.4	6
241	Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.. Blood, 2006, 108, 3878-3878.	1.4	0
242	Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution's Experience.. Blood, 2006, 108, 3062-3062.	1.4	0
243	Relationship between increased personal well-being and enhanced empathy among. Journal of General Internal Medicine, 2005, 20, 559-564.	2.6	335
244	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. Blood, 2005, 106, 938-938.	1.4	8
245	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. Blood, 2005, 106, 4698-4698.	1.4	0
246	Lymphocyte Count Persistence and Early Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. Blood, 2004, 104, 3252-3252.	1.4	3
247	Images and Reflections From Mayo Clinic Heritage. Mayo Clinic Proceedings, 2003, 78, 1324.	3.0	1
248	Images and Reflections From Mayo Clinic Heritage. Mayo Clinic Proceedings, 2002, 77, 1182.	3.0	2
249	Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. International Journal of Dermatology, 2002, 41, 352-356.	1.0	16
250	Images and reflections from Mayo Clinic heritage. Mayo Clinic Proceedings, 2002, 77, 964.	3.0	0
251	Rituximab Toxicity in Patients with Peripheral Blood Malignant B-cell Lymphocytosis. Leukemia and Lymphoma, 2001, 42, 1329-1337.	1.3	28
252	Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2001, 42, 1235-1241.	1.3	6



#	ARTICLE	IF	CITATIONS
253	Fulminant Hepatic Failure Secondary to Adenovirus Following Fludarabine-Based Chemotherapy for Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 1145-1150.	1.3	7
254	Smoking and Risk of Non-Hodgkin Lymphoma Subtypes in a Cohort of Older Women. <i>Leukemia and Lymphoma</i> , 2000, 37, 341-349.	1.3	48
255	Testicular lymphoma is associated with a high incidence of extranodal recurrence. <i>Cancer</i> , 2000, 88, 154-161.	4.1	147
256	Author reply. <i>Cancer</i> , 2000, 89, 714-714.	4.1	2
257	Primary Laryngeal Lymphoma. <i>Laryngoscope</i> , 1997, 107, 1502-1506.	2.0	50
258	Nasal and Nasopharyngeal Angiocentric T-Cell Lymphomas. <i>Laryngoscope</i> , 1996, 106, 139-143.	2.0	33
259	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. <i>Liver Transplantation</i> , 1996, 2, 375-382.	1.8	71
260	S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. <i>Cancer</i> , 1995, 76, 1059-1064.	4.1	7
261	Neurological complications of peripheral and cutaneous T-cell lymphomas. <i>Annals of Neurology</i> , 1994, 36, 625-629.	5.3	42
262	Peripheral T-cell lymphoma involving the placenta. <i>Cancer</i> , 1992, 70, 2963-2968.	4.1	29
263	Cytogenetic findings in 21 cases of peripheral T-Cell lymphoma. <i>American Journal of Hematology</i> , 1990, 35, 88-95.	4.1	20
264	Rapid S-Phase Determination of Non-Hodgkin's Lymphomas with the Use of an Immunofluorescence Bromodeoxyuridine Labeling Index Procedure. <i>American Journal of Clinical Pathology</i> , 1989, 91, 298-301.	0.7	13
265	Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018). <i>American Journal of Hematology</i> , 0, , .	4.1	4